In an earnings call covering its 2024 full-year results, executives from Ekso Bionics (Nasdaq: EKSO) described the company’s plans to get its Ekso Indego Personal exoskeleton into the hands of more patients. “Revenue of $17.9 million was down from $18.3 million for the same period in 2023,” Ekso Bionics CFO Jerome Wong said, in describing…